Chemed Corporation (NYSE:CHE) Shares Sold by Impax Asset Management Group plc

Impax Asset Management Group plc decreased its holdings in shares of Chemed Corporation (NYSE:CHE - Free Report) by 9.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 301,580 shares of the company's stock after selling 30,877 shares during the period. Chemed makes up about 1.1% of Impax Asset Management Group plc's holdings, making the stock its 28th biggest position. Impax Asset Management Group plc owned approximately 2.06% of Chemed worth $185,568,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Neuberger Berman Group LLC increased its position in Chemed by 1.2% during the 4th quarter. Neuberger Berman Group LLC now owns 501,562 shares of the company's stock worth $265,726,000 after purchasing an additional 5,809 shares during the period. Geode Capital Management LLC increased its position in Chemed by 1.5% during the 4th quarter. Geode Capital Management LLC now owns 340,409 shares of the company's stock worth $180,654,000 after purchasing an additional 4,966 shares during the period. FMR LLC increased its position in Chemed by 18.9% during the 4th quarter. FMR LLC now owns 283,790 shares of the company's stock worth $150,352,000 after purchasing an additional 45,174 shares during the period. JPMorgan Chase & Co. increased its position in Chemed by 8.2% during the 4th quarter. JPMorgan Chase & Co. now owns 266,786 shares of the company's stock worth $141,343,000 after purchasing an additional 20,310 shares during the period. Finally, Epoch Investment Partners Inc. increased its position in Chemed by 5.1% during the 4th quarter. Epoch Investment Partners Inc. now owns 252,237 shares of the company's stock worth $133,635,000 after purchasing an additional 12,167 shares during the period. Institutional investors and hedge funds own 95.85% of the company's stock.

Insider Buying and Selling

In related news, CEO Kevin J. Mcnamara sold 1,500 shares of the company's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $576.45, for a total value of $864,675.00. Following the sale, the chief executive officer owned 101,197 shares of the company's stock, valued at approximately $58,335,010.65. This represents a 1.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Spencer S. Lee sold 1,500 shares of the company's stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $577.99, for a total value of $866,985.00. Following the completion of the sale, the executive vice president directly owned 14,627 shares in the company, valued at approximately $8,454,259.73. The trade was a 9.30% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,500 shares of company stock worth $2,598,450. 3.29% of the stock is owned by corporate insiders.

Chemed Price Performance

Shares of NYSE:CHE opened at $472.61 on Friday. The business's 50 day simple moving average is $555.54 and its 200-day simple moving average is $562.58. The firm has a market capitalization of $6.91 billion, a price-to-earnings ratio of 23.02, a price-to-earnings-growth ratio of 2.28 and a beta of 0.50. Chemed Corporation has a 12 month low of $469.80 and a 12 month high of $623.61.

Chemed (NYSE:CHE - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The company reported $5.63 EPS for the quarter, topping the consensus estimate of $5.59 by $0.04. The business had revenue of $646.94 million for the quarter, compared to analyst estimates of $641.78 million. Chemed had a return on equity of 27.58% and a net margin of 12.40%. The company's quarterly revenue was up 9.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.20 EPS. On average, equities analysts anticipate that Chemed Corporation will post 21.43 earnings per share for the current year.

Chemed Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 17th. Investors of record on Thursday, May 29th were paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 0.42%. The ex-dividend date of this dividend was Thursday, May 29th. Chemed's payout ratio is currently 9.74%.

Analyst Ratings Changes

CHE has been the topic of several recent analyst reports. Royal Bank Of Canada reiterated an "outperform" rating and set a $640.00 target price (down previously from $674.00) on shares of Chemed in a research report on Monday, June 30th. Bank of America decreased their price target on Chemed from $708.00 to $650.00 and set a "buy" rating on the stock in a research note on Monday, June 30th. Finally, Wall Street Zen lowered Chemed from a "buy" rating to a "hold" rating in a research note on Saturday.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.